Aarti Pharmalabs Limited sees a credit rating action

I couldn't find relevant information for this query. Please try rephrasing or asking about a specific metric.

I couldn't find relevant information for this query. Please try rephrasing or asking about a specific metric.

Verdict: The Rs 59.50 crore demand is small relative to Aarti Pharmalabs’ net worth but large relative to its immediately available cash. It is also materially above the company’s recent reported provision balances, although the available figures do not establish that those provisions were specifically for tax or customs duty.

Balance-sheet comparison

Using consolidated total equity as the closest reported proxy for net worth, Aarti Pharmalabs had equity of Rs 2,124.6 Crores in Q1 FY27 ^[1]. Consolidated cash and equivalents were Rs 8.53 Crores ^[2].

• Vs net worth: Rs 59.50 crore equals approximately 2.80% of reported net worth.
• Vs cash: The demand is approximately 6.98 times cash, exceeding cash and equivalents by about Rs 50.97 Crores.
• Interpretation: The amount is not large enough, on its own, to represent a major erosion of the equity base, but it is significant from a liquidity perspective because cash alone would cover only about 14% of the demand.

Comparison with recent provision levels

The reported current and non-current provision balances were:

• Q2 FY26: Rs 11.96 crore current provisions plus Rs 6.68 crore non-current provisions, or Rs 18.64 Crores in aggregate ^{[3] [4]}.
• Q4 FY26 and Q1 FY27: Rs 11.22 crore current provisions plus Rs 7.85 crore non-current provisions, or Rs 19.07 Crores in aggregate ^{[3] [4]}.

The Rs 59.50 crore demand is therefore approximately 3.1 times the recent aggregate provision balance. It is also about 2.95 times the Q1 FY27 current-tax charge of Rs 20.14 Crores ^[5] and 2.39 times the Q1 FY27 total tax expense of Rs 24.92 Crores ^[6].

Analytical read: Yes, the demand represents a material deviation from the scale of provisions typically reflected in the recent balance-sheet snapshots. However, that conclusion should not be overstated: the reported provision lines are not identified as tax/duty-specific, and the accounting treatment of the Rs 59.50 crore demand—provision, contingent liability, payment obligation, or disputed amount—is not established by these figures alone.